Xeris Pharmaceuticals has dosed the first subject in a Phase 2 trial with its developmental ready-to-use glucagon in patients who experience hypoglycemic episodes following bariatric surgery.
AstraZeneca announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.
Acceleron Pharma, a biopharmaceutical company focused on the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept.
Imbrium Therapeutics, an operating subsidiary of Purdue Pharma, is advancing its novel, potentially first-in-class small molecule IMB-115 (previously referred to as IT-1315) to a Phase 2 clinical study following favorable results from Phase 1 studies evaluating the molecule’s safety and tolerability, including its potential for abuse and interaction with alcohol.
TILT Biotherapeutics has joined forces with Merck and Pfizer to evaluate the combination of its oncolytic adenovirus TILT-123 ((Ad5/3-E2F-D24-TNFa-IRES-IL2) with the duo’s avelumab for the treatment of solid tumours that are refractory to routine modalities.
NantKwest announced that the company’s PD-L1 t-haNK investigational new drug application (IND) has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid cancers.
Horizon Therapeutics has announced the initiation of a clinical trial evaluating KRYSTEXXA (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD).
Ironwood Pharmaceuticals and Allergan said that their guanylate cyclase-C (GC-C) agonist LINZESS (linaclotide) 290mcg succeeded in a phase 3b trial on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C).
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.